Methotrexate-induced changes in the concentration of antibodies to modified citrulnated vimentin in blood serum of patients with rheumatoid arthritis
- 作者: Shilkina N.1, Voronina M.1, Vinogradov A.1, Borisova O.2, Shilkina N3, Voronina M3, Vinogradov A3, Borisova O4
-
隶属关系:
- Ярославская государственная медицинская академия
- Муниципальная клиническая больница МЧС НЯ НПЗ
- State Medical Academy, Yaroslavl
- Municipal hospital , Yaroslavl
- 期: 卷 83, 编号 5 (2011)
- 页面: 10-13
- 栏目: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/30824
- ID: 30824
如何引用文章
全文:
详细
Material and methods. A 12-month trial included 76 patients with verified rheumatoid arthritis (RA). Methotrexate per os was given in a dose 7.5-10 mg/week to 44(57.9%) patients, 25 patients received no basic therapy. Anti-MCV (IU/ml) were detected with commercial chemicals made in Germany (ORGENTEC).
Results. RA patients given methotrexate doses 7.5 and 10 mg/week and untreated with basic anti-inflammatory drugs showed no significant differences by basic clinical and device parameters, level of anti-MCV at primary examination and 12 months later.
Conclusion. Anti-MCV titer cannot be used for control of efficacy of methotrexate treatment in doses 75 and 10 mg/week, choice of individual effective doses.
作者简介
Natal'ya Shilkina
Ярославская государственная медицинская академия
Email: shilkin39@mail.ru
д-р мед. наук, проф., зав. каф. пропедевтики внутренних болезней Ярославской государственной медицинской академии, тел.: (4852) 300210; Ярославская государственная медицинская академия
Mariya Voronina
Ярославская государственная медицинская академия
Email: knopselgula@rambler.ru
аспирант каф. пропедевтики внутренних болезней Ярославской государственной медицинской академии; Ярославская государственная медицинская академия
Aleksey Vinogradov
Ярославская государственная медицинская академия
Email: vinograd@fromru.com
канд. мед. наук, асс. каф. пропедевтики внутренних болезней; Ярославская государственная медицинская академия
Ol'ga Borisova
Муниципальная клиническая больница МЧС НЯ НПЗ
Email: propedevtik@mail.ru
зав. иммунологической лаб. Муниципальной клинической больницы МСЧ НЯ НПЗ; Муниципальная клиническая больница МЧС НЯ НПЗ
N Shilkina
State Medical Academy, YaroslavlState Medical Academy, Yaroslavl
M Voronina
State Medical Academy, YaroslavlState Medical Academy, Yaroslavl
A Vinogradov
State Medical Academy, YaroslavlState Medical Academy, Yaroslavl
O Borisova
Municipal hospital , YaroslavlMunicipal hospital , Yaroslavl
参考
- Сигидин Я. А., Лукина Г. В. Новые подходы к анализу патогенеза и патогенетической терапии ревматоидного артрита. Науч.-практ. ревматол. 2001; 5: 4-11.
- Насонов Е. Л. Почему необходимы ранняя диагностика и лечение ревматоидного артрита? Рус. мед. журн. 2002; 22 (10): 1009-1010.
- Ursum J., Nielen M. M., van Schaardenburg D. et al. Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study. Arthr. Res. Ther. 2008; 10 (1): R 12.
- Bang H., Egerer K., Gauliard A. et al. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthr. and Rheum. 2007; 56 (8): 2503-2511.
- Wagner E., Skoumal M., Bayer P. M. et al. Antibody against mutated citrullinated vimentin: a new sensitive marker in the diagnosis of rheumatoid arthritis. Rheumatol. Int. 2009; 28.
- Каратеев Д. Е., Лучихина Е. Л., Тюрина Л. Н. и др. Ранняя диагностика ревматоидного артрита в клинической практике на современном этапе (результаты наблюдений за московской когортой больных ранним артритом в рамках программы РАДИКАЛ). Тер. арх. 2008; 5: 8-13.
- Roland P. N., Grootenboer Mignot S. et al. Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy. Arthr. Res. Ther. 2008; 10 (6): 142.
- Klaasen R., Cantaert Т., Wijbrandts С. A. еt al. The relationship between different isotypes (IgM, IgG and IgA) of rheumatoid factor and IgG anticyclic citrullinated peptide antibody and clinical response to infliximab in rheumatoid arthritis. Arthr. and Rheum. 2009; 60: 373-374.
- Bobbio-Pallavicini F., Capoorali R., Alpini С. et al. High IgA rheumatoid factor levels are associated with poor clinical response to tumor necrosis factor alpha inhibitors in rheumatoid arthritis. Ann. Rheum. Dis. 2007; 66: 302-307.
- Braun-Moscovici Y., Markovits D., Zinder О. et al. Anticyclic citrullinated peptide antibodies as predictor of response to antitumor necrosis factor-alpha therapy in patients with rheumatoid arthritis. J. Rheumatol. 2006; 33: 497-500.
- Poter C., Hyrich K. L., Tracey A. et al. Association of rheumatoid factor and anticyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumor necrosis factor response in rheumatoid arthritis. Ann. Rheum. Dis. 2009; 68: 69-74.
- Tak P. P., Cohen S. B., Emery P. et al. Baseline autoantibody status (RF, ant-CCP) and clinical response following the first treatment course with rituximab. Arthr. and Rheum. 2006; 54 (9): 368.
- Silverman G. J., Schwartzman S., Townsend M. et al. Identification of biomarkers for enhanced benefit to Rituximab in rheumatoid arthritis: role for autoantibodies and inflammatory markers. Arthr. and Rheum. 2009; 60: 628.
- Isaacs J. D. et al. Autoantibody-positive RA patients have enhanced clinical response to rituximab when compared with seronegative patients. Ann. Rheum. Dis. 2009; 68 (3): 442.
- Mariette X., Kivitz A., Isaacs J. D. et al. Effectiveness of Rituximab (RTX) + methotrexate (MTX) in patients (pts) with early active rheumatoid arthritis (RA) and disease characteristics associated with poor outcomes. Arthr. and Rheum. 2009; 60: S631.
- Kang S. Y., Kim M. H. et al. Measurement of inflammatory cytokines in patients with rheumatoid arthritis. Korean J. Lab. Med. 2010; 30 (3): 301-306.